Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis

This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)

Inclusion Criteria:

• Male of female subjects, 18-65 years of age with a diagnosis of SPMS
• HLA DR2 and/or DR4 positive
• Absence of a relapse in the 3 months prior to baseline
• EDSS of 3.0 - 6.5

Exclusion Criteria:

• Therapy with Beta-interferon, glatiramer acetate within 3 months or mitoxantrone, cyclophosphamide, methotrexate, azathioprine or any immune modulating or immunosuppressive drugs within 6 months of baseline
• Treatment with Tysabri within 2 years of baseline
• Females who are breast feeding, pregnant (pregnancy test at baseline) or not using a medically approved method of contraception regularly

Other protocol-defined inclusion/exclusion criteria may apply.